Clinscience Now Kapadi

We are excited to announce that Clinscience has merged with OncoBay Clinical and Exom Group, and is now operating under a new unified brand: Kapadi. Therefore, the LinkedIn Profiles were merged as well: This transformative merger brings together three companies' extensive expertise and resources, creating a premier provider of global technology- and data-driven oncology clinical trial services. By leveraging our combined strengths, Kapadi is uniquely positioned to support your future trials with unparalleled efficiency, innovation, and scientific excellence. We look forward to partnering with you to advance the development of novel cancer therapies and improve patient outcomes worldwide- Clinscience is a global SMART CRO with hubs across five countries in Europe, the United States and India and has a satellite presence in additional 5 European countries. Since 2020, Clinscience offers full (end-to-end) CRO services from Protocol Development to Final Study Report. Over 150 Biotech Clients trust Our Brand and we expect many more in the near future. Our uncomplicated procedures and Data-driven approach harnessed with state-of-the-art technology allow us to be smart and agile in meeting our Clients’ needs. Clinscience specializes in Oncology, Hemato-Oncology, Cardiovascular Diseases, and Neurology. It has managed more than 500 studies for 24+ therapeutic areas and recruited over patients across 4,900+ sites globally. The Company’s procedures and Data-driven approach, harnessed with the Genius Suite™ technology, work together to give the Clients power and flexibility to address even the most unique needs. Clinscience is part of a publicly-traded parent company, Neuca Plc, an organization in the pharmaceutical wholesaling and healthcare industry that provides the structure to meet the needs of commercial and non-commercial studies. Visit for more information.